

SynThera Biomedical raises seed funds from 1Crowd, BIRAC

11 July 2018 | News

The company's flagship products SynOst and PoroSyn are synthetic bone graft substitute products made from bioactive glass materials.



SynThera Biomedical Private Limited, Pune-based healthcare startup which focuses on R&D, manufacture and commercialization of affordable biomaterials-based medical devices.

The company has secured an undisclosed amount of seed funding investment from two investors equity crowd-funding platform 1Crowd and the government's Biotechnology Industry Research Assistance Council (BIRAC) SEED scheme via Venture Center.

"The investment will help us achieve expansion, approvals and launch of our first line of bone graft substitute products in the market, together with further development and testing on our patented bone graft product line", said Nilay Lakhkar, founder and chief executive of SynThera Biomedical.

The company's flagship products SynOst and PoroSyn are synthetic bone graft substitute products made from bioactive glass materials.

Both products are used in dental and orthopaedic surgeries as implantable materials for repair and regeneration of bone that is lost or damaged due to disease, injuries or congenital deformities.